Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: A meta-analysis

Mao, Qunxia; Guo, Hao; Gao, Linggen; Wang, Hongwei; Ma, Xu

doi:10.3892/mmr.2013.1735

Cited by 14 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This polymorphism has an estimated frequency of 0.12 in a random Caucasian population [55]. This Pro12Ala substitution is associated with an increased incidence of colorectal cancer and breast cancer [56,57]. However, in investigating this Pro12Ala in PC, this polymorphism is not associated with increased PC risk or more aggressive disease [58].…”

Section: Pparγ Alterations In Prostate Cancermentioning

confidence: 99%

The role of PPARγ in prostate cancer development and progression

Hartley

Ahmad

2022

Br J Cancer

View full text Add to dashboard Cite

Advanced and metastatic prostate cancer is often incurable, but its dependency on certain molecular alterations may provide the basis for targeted therapies. A growing body of research has demonstrated that peroxisome proliferator-activated receptor gamma (PPARγ) is amplified as prostate cancer progresses. PPARγ has been shown to support prostate cancer growth through its roles in fatty acid synthesis, mitochondrial biogenesis, and co-operating with androgen receptor signalling. Interestingly, splice variants of PPARγ may have differing and contrasting roles. PPARγ itself is a highly druggable target, with agonists having been used for the past two decades in treating diabetes. However, side effects associated with these compounds have currently limited clinical use of these drugs in prostate cancer. Further understanding of PPARγ and novel techniques to target it, may provide therapies for advanced prostate cancer.

show abstract

Section: Pparγ Alterations In Prostate Cancermentioning

confidence: 99%

The role of PPARγ in prostate cancer development and progression

Hartley

Ahmad

2022

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…However, until this moment, studies investigating the association between PPARγ polymorphism and the risk of BC reported inconclusive results (8)(9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Difference in fatty acids composition of breast adipose tissue in women with breast cancer and benign breast disease

Conceição¹,

Dias²,

Pessoa³

et al. 2017

Nutr Hosp

View full text Add to dashboard Cite

Introduction: Breast cancer is the second most common cancer in the world, and the most frequent cancer among women. Moreover, there are factors that influence the risk for breast cancer including the age, genetic and endocrine factors, and lifestyle.Objectives: Evaluate the consumption of fatty acids; compare the fatty acids composition in the breast adipose tissue of women with breast cancer and benign breast disease as well as potential risk factors; and describe the genotypic frequency of the Pro12Ala PPARγpolymorphism.Material and Methods: A hospital-based case-control study was conducted including incident cases (n = 38 breast cancer; n = 75 benign breast disease; n = 166 control). Lifestyle features, socioeconomic issues, dietary intake, anthropometry, and blood and tissue data were assessed.Results: No differences were observed for fatty acids intake. Interestingly, lauric acid (P = 0.001), myristic acid (P = 0.036), stearic acid (P = 0.031), and total saturated fatty acids (SFAs) (P=0.048) had lower concentrations in BC than in BBD women, while palmitoleic acid (P = 0.022), erucic acid (P = 0.002), total monounsaturated fatty acids (MUFAs) (P = 0.039) and oleic acid/stearic acid ratio (P = 0.015) increased. There was no significant association between PPARγ polymorphism and studied groups (P = 0.977). The age at first full pregnancy (P = 0.004) was significantly associated with the development BC, whereas BMI (P = 0.005); percentage of body fat (P = 0.024); physical activity (P = 0.036); and age at menarche (P = 0.008), at first full pregnancy (P < 0.001), and of first mammogram (P = 0.018) were significantly associated with the development of BBD.Conclusion: The results suggest a different fatty acids composition of breast adipose tissue, a biomarker of long-term dietary intake, particularly for SFAs, MUFA and 18: 1 n-9/18: 00 ratio. Our findings also show that are differences in the factors related to the development of BC and BBC.

show abstract

“…Several SNPs in the PPARG gene have been discovered, and rs1801282 (Pro12Ala), with a minor allele frequency (MAF) of 0.07 (based on information from 1000 genome project), is the most studied one ( 16 , 17 ). Another polymorphism located in PPARG , rs3856806 (His449His), is a frequent PPARG synonymous/3′-untranslated region (3′-UTR) polymorphism (MAF = 0.127) ( 17 ).…”

mentioning

confidence: 99%

Impact of Proliferator-Activated Receptor γ Gene Polymorphisms on Risk of Schizophrenia: A Case-Control Study and Computational Analyses

Sargazi

Moudi

et al. 2020

IJPS

View full text Add to dashboard Cite

Objective: Schizophrenia (SCZ) is a common psychiatric disorder characterized by a complex mode of inheritance. Peroxisome proliferator-activated receptor-γ (PPARG) mainly regulates lipid and glucose metabolisms while it is constitutively expressed in rat primary microglial cultures. This preliminary study was aimed to investigate the relationship of two polymorphisms in the PPARG gene, rs1801282 C/G, and rs3856806 C/T, to the risk of SCZ in the southeast Iranian population. Method: A total of 300 participants (150 patients with SCZ and 150 healthy controls) were enrolled. Genotyping was done using the amplification refractory mutation system polymerase chain reaction (ARMS–PCR) technique. Computational analyses were carried out to predict the potential effects of the studied polymorphisms. Results: A significant link was found between genotypes of rs1801282 and SCZ susceptibility. The G allele of rs1801282 in CG and GG form of the codominant model increased the risk of SCZ by 2.49 and 2.64 folds, respectively. With regards to rs3856806, enhanced risk of SCZ was also observed under different inheritance models except for the overdominant model. Also, the T allele of rs3856806 enhanced the risk of SCZ by 3.19 fold. Computational analyses predicted that rs1801282 polymorphism might alter the secondary structure of PPARG-mRNA and protein function. At the same time, the other variant created the binding sites for some enhancer and silencer motifs. Conclusion: Our findings showed that PPARG rs1821282 and rs3856806 polymorphisms associate with SCZ susceptibility. Replication studies in different ethnicities with a larger population are needed to validate our findings.

show abstract

Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: A meta-analysis

Cited by 14 publications

References 25 publications

The role of PPARγ in prostate cancer development and progression

The role of PPARγ in prostate cancer development and progression

Difference in fatty acids composition of breast adipose tissue in women with breast cancer and benign breast disease

Impact of Proliferator-Activated Receptor γ Gene Polymorphisms on Risk of Schizophrenia: A Case-Control Study and Computational Analyses

Contact Info

Product

Resources

About